This finding suggests that, in men with prostate cancers bearing the TMPRSS2-ERG fusion, a short course of androgen ablation might upregulate PSMA and facilitate therapeutic targeting and/or imaging based on PSMA. Here, FOLH1 is linked to prostate carcinoma.